Cite

    Nakamura, Y. et al. (2016). Linagliptin inhibits lipopolysaccharide-stimulated interleukin-6 production, intranuclear p65 expression, and p38 mitogen-activated protein kinase phosphorylation in human umbilical vein endothelial cells. Renal replacement therapy. 2 (1), pp. 1-10. [Online].